Type 2 Diabetes
9 videos · last 6 months shuffled daily, then older videos newest first
▶
1:46:58 From Wellness App to Digital Health Application: Building a Digital Therapeutic in Europe - E5
GCP-Mindset's Beyond Outcomes talks to Vitadio co-founder Lenka Šomvárska about generating clinical evidence, CE marking and the MDR transition for a type 2 diabetes digital therapeutic.
▶
1:03 QWINT-1: Once-Weekly Insulin Efsitora in Type 2 Diabetes
WeTrials summarises the Phase 3 QWINT-1 trial behind the FDA approval of once-weekly insulin efsitora for type 2 diabetes, in which 795 adults saw A1C fall by a similar amount to daily insulin glargine over 52 weeks.
▶
53:00 The Future of Diabetes Treatment: Beta Cell Regeneration
Michael G. King of Rodman & Renshaw talks to endocrinologist Dr. Alex Abitbol about beta cell regeneration and the evolving diabetes treatment landscape.
▶
5:22 TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity
New Phase 3 TRIUMPH-2 data suggest retatrutide produces substantial weight loss alongside glycemic improvement in people with type 2 diabetes.
▶
9:25 Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3
Diana Isaacs, PharmD, and Natalie Bellini, DNP, on topline Phase 3 TRIUMPH-3 results for retatrutide, a triple agonist, in adults with obesity.
▶
52:06 The Latest Therapeutic Developments for Type 1 Diabetes Post-ADA
Piper Sandler analyst Ted Tenthoff and Joslin Diabetes Center's Dr. Rohit Kulkarni discuss type 1 diabetes data from ADA 2026, including teplizumab, beta cell regeneration and menin inhibition.
▶
6:19 Stanford Diabetes Research Center Employee Discusses How to Get Involved In Diabetes Clinical Research
Stanford University Diabetes Researcher discusses observational studies and interventional trials and why people should participate in clinical trials along with a link to a list of all of the Diabetes clinical trials at Stanford and description of how their online patient screener works.
▶
59:14 Oral Insulin ORMD-0801 in Type 2 Diabetes: Expert Webinar
Anne Peters of Keck School of Medicine of USC and former FDA official Alexander Fleming discuss the type 2 diabetes treatment landscape and ORMD-0801, Oramed's oral insulin candidate in Phase 3 trials.
▶
2:11 Clinical Trial Looks at Type 2 Diabetes as an Indicator for Pancreatic Cancer
A clinical trial sponsored by Bluestar Genomics is underway in Palm Beach, Florida and is looking for patients recently diagnosed with Type 2 Diabetes to see if Type 2 Diabetes can be used as an indicator and way of detecting pancreatic cancer in its early stages.